MoonLake Stock (NASDAQ:MLTX), Trade Ideas

MoonLake

MoonLake Immunotherapeutics is a clinical-stage biotechnology company engaged in leveraging Nanobody technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases. The company derives maximum revenue from United Kingdoms.

MLTX

Biotech

Equities

News

Health Care

Movers

Trading Ideas

General

ABBV

Results with MoonLake Immunotherapeutics&#39; Nanobody sonelokimab in Psoriatic Arthritis. Achieve over 60% ACR50, 40% ACR70, and 80% PASI90 by week 24. Unprecedented improvements compared to competitors.

Why Is Inflammatory Disease-Focused MoonLake Immunotherapeutics Stock Trading Higher Today?

Small Cap

Intraday Update

Markets

ARVN

ARWR

CLDX

CRNX

DELL

EVBG

NTAP

OPRA

PTCT

RDNT

RGNX

RMBS

ROOT

RPAY

SANA

SMCI

XPOF

YMAB

U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.

Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday

Earnings

Penny Stocks

Eurozone

Commodities

Global

CREV

DBGI

DISH

SATS

U.S. stocks turned lower toward the end of trading, with the Dow Jones falling around 50 points on Monday

The Dow traded down 0.16% to 34,007.81 while the NASDAQ fell 0.08% to 13,467.42. The S&amp;P 500 also fell, dropping, 0.13% to 4,352.49.

Dow Turns Lower; EchoStar Shares Plunge

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake Immunotherapeutics

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Buy and maintains $100 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $100 Price Target

Moonlake Immunotherapeutics Penned Three-year Technology Partnership With Komodo Health To Advance Research On Inflammatory Skin And Joint Conditions

Needham analyst Serge Belanger reiterates MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Buy and maintains $66 price target.

Needham Reiterates Buy on MoonLake, Maintains $66 Price Target

Goldman Sachs analyst Richard Law initiates coverage on MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Neutral rating and announces Price Target of $62.

Initiation

Goldman Sachs Initiates Coverage On MoonLake with Neutral Rating, Announces Price Target of $62

<a href="https://www.betaville.co.uk/betaville-intelligence/uncooked-alert-moonlake-immunotherapeutics-said-to/" title="https://www.betaville.co.uk/betaville-intelligence/uncooked-alert-moonlake-immunotherapeutics-said-to/">https://www.betaville.co.uk/betaville-intelligence/uncooked-alert-moonlake-immunotherapeutics-said-to/</a>

Watching MoonLake Immunotherapeutics; Shares Spike Higher, Traders Circulate Comments From Betaville

Wedbush analyst Andreas Argyrides reiterates MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Outperform and maintains $92 price target.

Wedbush Reiterates Outperform on MoonLake, Maintains $92 Price Target

On Sunday,&nbsp;MoonLake Immunotherapeutics&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) announced that continued treatment with Nanobody sonelokimab led to significant improvements across all key outcomes at 24-week data from the ARGO&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/03/g37576995/moonlake-announces-significant-improvements-with-nanobody-sonelokimab-over-24-weeks-in-active-psor" rel="noreferrer noopener">trial in psoriatic arthritis (PsA)</a>.
The 207-patient ARGO trial demonstrated that the primary endpoint, the American College of Rheumatology (ACR) 50, continued to improve from week 12 and&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/11/35621418/why-is-arthritis-focused-moonlake-immunotherapeutics-stock-trading-lower-today" rel="noreferrer noopener">exceeded 60% by week 24</a>.&nbsp;
The more rigorous ACR70 outcome was achieved by approximately 40% of patients by week 24.&nbsp;
In addition, by week 24, over 80% and 60% of patients treated with sonelokimab achieved Psoriasis Area Severity Index (PASI) 90 and 100, respectively. Both doses of sonelokimab yielded similar results. 
The company said the responses surpassed those for&nbsp;AbbVie Inc&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) Humira (adalimumab), the active reference arm in the study, and were also higher when indirectly compared to competitors using the same active reference arm as a standard.
Treatment with sonelokimab resulted in unprecedented improvements in composite scores that reflect responses in different domains simultaneously.&nbsp;
ACR50+PASI90 up to 59%, ACR 50+PASI 100 up to 52%, ACR 70+PASI 100 up to 48%, and MDA up to 61% response.&nbsp;
In all composite scores, sonelokimab showed 16-29 percentage point differences to the reference adalimumab arm, comparatively higher than competitors using the same reference arm.&nbsp;
Monthly maintenance with 60mg or 120mg doses showed leading responses above the TNF reference arm across all key outcomes, including in higher treatment goals (ACR70, PASI100, composites) – 120mg added benefit for specific patient subgroups.
The safety profile of sonelokimab was consistent with previous trials, and no new safety signals were detected.&nbsp;
MoonLake intends to commence Phase 3 trials in hidradenitis suppurativa (HS) in the second quarter 2024 under the VELA program that will enroll 800 patients, with top-line primary endpoint data expected as early as mid-2025.
MoonLake says it would commence four additional clinical trials of sonelokimab across dermatology and rheumatology, including palmo-plantar pustulosis, juvenile HS, and seronegative spondyloarthritis.
Price Action: MLTX shares are up 3% at $46.98 on the last check Monday.

WIIM

MoonLake Immunotherapeutics shares are trading higher after the company announced improvements across all key outcomes from its 24-week data from the ARGO trial in psoriatic arthritis and other R&D updates.

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Buy and raises the price target from $75 to $100.

HC Wainwright & Co. Maintains Buy on MoonLake, Raises Price Target to $100

Sunday, MoonLake Immunotherapeutics Said Continued Treatment With Nanobody Sonelokimab Led To Significant Improvements Across All Key Outcomes At 24-week Data From ARGO Trial In Psoriatic Arthritis

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody&#xAE; sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
ZUG, Switzerland,&nbsp;March 4, 2024 – MoonLake Immunotherapeutics (("MoonLake", NASDAQ:<a href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that 24-week data from its Phase 2 MIRA trial with the Nanobody sonelokimab in moderate to severe hidradenitis suppurativa (HS), will be presented in a late breaking oral session on March 10 at 14:00 PST at the 2024 <a href="https://www.globenewswire.com/Tracker?data=DI_-4ogSt4b2SXJEVnGpEtJPCE4adFiskjFaRmDIBH4iSO_SDBPprGf0HByTSi4mZ0DQhXw9e53r1U1Kxdp4spdspYAnjAX2hsBwE3qH320=">American Academy of Dermatology</a> (AAD) Annual Meeting, taking place from March 8-12, in San Diego, California.
Kristian Reich, MD, PhD, Chief Scientific Officer at MoonLake&nbsp;commented: "We are pleased that the 24-week data from our Phase 2 MIRA trial has been selected by the American Academy of Dermatology as an oral late-breaking presentation. Hidradenitis suppurativa is a severely debilitating chronic skin condition and the data will showcase the therapeutic effect of maintenance treatment with our Nanobody&#xAE; sonelokimab."
The oral presentation titled "Efficacy and safety of the IL-17A- and IL-17F-inhibiting Nanobody&#xAE; sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS): Week 24 results from the Phase 2 MIRA trial" will be presented by Professor Brian Kirby MD, FRCPI, Department of Dermatology, St. Vincent's University Hospital and Charles Institute of Dermatology, University College Dublin, Dublin, Ireland. The presentation will be held on Sunday 10 March at 14:00 PST / 17:00 EST / 23:00 CET during the late breaking research session 2 (S050) in room 20B.
Key members of the MoonLake team, including the executive leadership team, will attend AAD. In June 2023, MoonLake <a href="https://www.globenewswire.com/Tracker?data=kZaVm-lZfWvR0k7WidTVg7XcsWB7QRzHbZYjJsrUlsBFTLdjfckbrZMfZyJW4juSwc4RpeF1_79zjRC1Xy3Se6x3uPvKjJ2t1eKIY_BJZFQkAfUw7wZQZRWvsZraIA5lKlz9-FjK-Fe3X6niLmmjBX77r1iHMEG6pn3srdL3Ke6kp8Tzop6_3Lccv3u_o0ikwFzHvwcEoMF6vdq4UPLcCQ==">announced</a> that the MIRA trial achieved a landmark milestone with positive top-line 12-week data using HiSCR75 as the primary endpoint and later presented the data at a late-breaking session at the European Academy of Dermatology and Venereology Congress in October. This was followed by an <a href="https://www.globenewswire.com/Tracker?data=kZaVm-lZfWvR0k7WidTVg9wabD-jOk0JJVbeV-RZF8xhbthaM-9WzzQDh-xIzeFqObm92ICThz7DtgMJSyjftSz8JKVTpECk7bFDOr3Vgry-jpU0RuFXKb1DS1hzCl5woK9xz0CpQGDGmsQHzzSB_NTtpDjioeG8kDoKYuEGg4DBmlYrPLYAhHNdZtsnzlZ_ACm7XEE9CFoWLj62fTAczQRZq-XvHK1MKsbS_qHPyfA=">announcement</a> in October 2023, reporting from the trial at 24 weeks, further establishing sonelokimab as a highly promising and differentiated therapeutic solution for HS. Sonelokimab is not yet approved for use in any indication.

Events

Moonlake Immunotherapeutics To Present Mira Trial Data Of Nanobody Sonelokimab In Hidradenitis Suppurativa As A Late Breaker At The AAD Annual Meeting 2024

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Buy and maintains $75 price target.

HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $75 Price Target

U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.
Shares of The Cooper Companies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/coo#NYSE">COO</a>) rose sharply during Friday&rsquo;s session after the company reported better-than-expected first-quarter <a href="https://www.benzinga.com/quote/COO/earnings">financial results and raised guidance</a>.
Cooper Companies posted adjusted earnings of 85 cents per share, beating market estimates of 78 cents per share. The company&rsquo;s quarterly sales came in at $931.60 million versus expectations of $915.94 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
The Cooper Companies shares rose 7.4% to $100.61 on Friday.
Here are some other big stocks recording gains in today&rsquo;s session.
<ul>
<li>Dell Technologies Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dell#NYSE">DELL</a>) jumped 26.3% to $119.52 as the company reported better-than-expected fourth-quarter financial results and increased its annual cash dividend by 20%.</li>
<li>Sweetgreen, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sg#NYSE">SG</a>) rose 26% to $16.05 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Everbridge, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evbg#NASDAQ">EVBG</a>) climbed 24.5% to $35.19 after it amended and restated the previously announced merger agreement with Thoma Bravo.</li>
<li>NetApp, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntap#NASDAQ">NTAP</a>) shares rose 24.4% to $110.85 after the company reported better-than-expected third-quarter financial results and issued guidance.</li>
<li>Xponential Fitness, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/xpof#NYSE">XPOF</a>) surged 24% to $12.50 following strong quarterly sales.</li>
<li>Opera Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/opra#NASDAQ">OPRA</a>) rose 18.8% to $14.47 following strong sales.</li>
<li>REGENXBIO Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rgnx#NASDAQ">RGNX</a>) rose 18.5% to $20.66.</li>
<li>RadNet, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdnt#NASDAQ">RDNT</a>) gained 18.1% to $44.71 following strong quarterly results.</li>
<li>Sana Biotechnology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sana#NASDAQ">SANA</a>) gained 17.3% to $11.78 after the company reported a year-over-year increase in fourth-quarter financial results.</li>
<li>Tidewater Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tdw#NYSE">TDW</a>) rose 15.3% to $80.73 following fourth-quarter financial results.</li>
<li>Y-mAbs Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ymab#NASDAQ">YMAB</a>) climbed 14.3% to $19.09 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Repay Holdings Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rpay#NASDAQ">RPAY</a>) gained 14.4% to $9.94 following upbeat quarterly results.</li>
<li>Root, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/root#NASDAQ">ROOT</a>) climbed 14.2% to $36.66. Jefferies analyst Yaron Kinar upgraded Root from Hold to Buy and raised the price target from $10 to $40.</li>
<li>Crinetics Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crnx#NASDAQ">CRNX</a>) gained 12.1% to $45.91 following quarterly results.</li>
<li>MasTec, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mtz#NYSE">MTZ</a>) gained 11.2% to $83.89 following strong quarterly results.</li>
<li>PTC Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ptct#NASDAQ">PTCT</a>) rose 10.4% to $31.11 following quarterly results.</li>
<li>Rambus Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rmbs#NASDAQ">RMBS</a>) climbed 9.3% to $64.76. Rambus initiated accelerated share repurchase program to repurchase an aggregate of $50 million of its common stock.</li>
<li>Arrowhead Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arwr#NASDAQ">ARWR</a>) rose 9.3% to $35.10.</li>
<li>Lotus Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lot#NASDAQ">LOT</a>) gained 9.3% to $8.13.</li>
<li>Transocean Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rig#NYSE">RIG</a>) climbed 9.3% to $5.12.</li>
<li>Arvinas, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arvn#NASDAQ">ARVN</a>) gained 9.2% to $50.21. Barclays analyst Peter Lawson maintained Arvinas with an Overweight and raised the price target from $26 to $60.</li>
<li>Celldex Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cldx#NASDAQ">CLDX</a>) climbed 8.7% to $52.27. Celldex Therapeutics priced upsized $400 million public offering of 8.52 million common stock at $47 per share.</li>
<li>Dyne Therapeutics, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dyn#NYSE">DYN</a>) gained 7.9% to $29.03.</li>
<li>Celestica Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cls#NYSE">CLS</a>) rose 7.7% to $45.81.</li>
<li>MoonLake Immunotherapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mltx#NASDAQ">MLTX</a>) gained 6.6% to $51.40. Needham analyst Serge Belanger reiterated MoonLake with a Buy and maintained a $66 price target.</li>
<li>Super Micro Computer, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smci#NASDAQ">SMCI</a>) rose 6.3% to $921.40.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37422012/bitcoin-ethereum-move-lower-sats-mantle-among-top-losers"> Bitcoin, Ethereum Move Lower; SATS, Mantle Among Top Losers</a>

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody&#xAE; sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
<ul>
<li>Clarified path for HS Phase 3 program with study design, patient population and endpoints agreed</li>
<li>One dose of SLK (120mg) to be tested with a similar protocol as in Phase 2</li>
<li>Total Phase 3 population of 800 patients to be complemented by Phase 2 population for registration</li>
<li>Phase 3 trial has similar design to validated Phase 2 trial and in line with the Company's communications and expectations</li>
<li>First patient expected to be randomized in Q2 2024, primary endpoint readout expected mid-2025
<ul>
<li>Further details to be provided in upcoming R&amp;D Day</li>
</ul>
</li>
</ul>

MoonLake Immunotherapeutics Announces FDA And EMA Feedback For Regulatory Path For Phase 3 Program Of Nanobody Sonelokimab In Hidradenitis Suppurativa

Wolfe Research analyst Andy Chen initiates coverage on MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Outperform rating.

Wolfe Research Initiates Coverage On MoonLake with Outperform Rating

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Now, 3/14/2024, According to Top Analysts

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Argenx Se (ARGX – Research Report) and MoonLake Immu...

Analysts' Top Healthcare Picks: Argenx Se (ARGX), MoonLake Immunotherapeutics (MLTX)

Goldman starts MoonLake at neutral, cites lead drug potential

Analyst Serge Belanger from Needham maintained a Buy rating on MoonLake Immunotherapeutics (MLTX – Research Report) and keeping the price target at...

MoonLake Immunotherapeutics: A Strong Buy on Innovation and Strategic Market Positioning

MoonLake Immunotherapeutics (MLTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selv...

MoonLake Immunotherapeutics Buy Rating: Strategic Partnerships and Market Potential Fuel Optimism

Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on MoonLake Immunotherapeutics (MLTX – Research Report). The associated p...

Buy Rating Affirmed for MoonLake Immunotherapeutics Amid Promising Clinical Results for Sonelokimab

H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on MLTX stock, giving a Buy rating yesterday. Ram Selvaraju's rating is b...

MoonLake Immunotherapeutics: A Promising Outlook with Sonelokimab's Potential in the HS Market

3 Best Stocks to Buy Now, 4/24/2024, According to Top Analysts

ARGX

AVGO

BHVN

MIRM

Press Releases

MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress

MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis

MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

Retail Sales

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day